{
    "contributors": [
        {
            "affiliation": "Allergan", 
            "email": null, 
            "full_name": "Medical Director", 
            "role": "Study Director"
        }
    ], 
    "date_processed": "June 09, 2014", 
    "description": "\n      This study will evaluate the safety and efficacy of BOTOX\u00ae treatment in Korean adults with\n      chronic migraine.\n    ", 
    "files": [
        "../ct_xml/NCT02147561.xml", 
        "../ct_raw_json/NCT02147561_raw.json"
    ], 
    "imported_from": "clinicaltrials.gov", 
    "raw": "{\n    \"clinical_study\": {\n        \"@rank\": \"1\", \n        \"arm_group\": {\n            \"arm_group_label\": \"botulinum toxin Type A\", \n            \"arm_group_type\": \"Experimental\", \n            \"description\": \"Botulinum toxin Type A injected across specific head and neck muscles on Day 0.\"\n        }, \n        \"brief_summary\": {\n            \"textblock\": \"This study will evaluate the safety and efficacy of BOTOX\\u00ae treatment in Korean adults with\\n      chronic migraine.\"\n        }, \n        \"brief_title\": \"A Safety and Efficacy Study of BOTOX\\u00ae in Korean Adults With Chronic Migraine\", \n        \"completion_date\": {\n            \"#text\": \"January 2015\", \n            \"@type\": \"Anticipated\"\n        }, \n        \"condition\": \"Migraine Disorders\", \n        \"condition_browse\": {\n            \"mesh_term\": \"Migraine Disorders\"\n        }, \n        \"eligibility\": {\n            \"criteria\": {\n                \"textblock\": \"Inclusion Criteria:\\n\\n          -  Ethnically Korean with a diagnosis of chronic migraine\\n\\n        Exclusion Criteria:\\n\\n          -  Anticipated need for botulinum toxin treatment for any reason other than chronic\\n             migraine during the study\\n\\n          -  Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral\\n             sclerosis\"\n            }, \n            \"gender\": \"Both\", \n            \"healthy_volunteers\": \"No\", \n            \"maximum_age\": \"N/A\", \n            \"minimum_age\": \"18 Years\"\n        }, \n        \"enrollment\": {\n            \"#text\": \"200\", \n            \"@type\": \"Anticipated\"\n        }, \n        \"firstreceived_date\": \"May 22, 2014\", \n        \"has_expanded_access\": \"No\", \n        \"id_info\": {\n            \"nct_id\": \"NCT02147561\", \n            \"org_study_id\": \"191622-148\"\n        }, \n        \"intervention\": {\n            \"arm_group_label\": \"botulinum toxin Type A\", \n            \"description\": \"Botulinum toxin Type A injected across specific head and neck muscles on Day 0.\", \n            \"intervention_name\": \"botulinum toxin Type A\", \n            \"intervention_type\": \"Biological\", \n            \"other_name\": [\n                \"BOTOX\\u00ae\", \n                \"onabotulinumtoxinA\"\n            ]\n        }, \n        \"intervention_browse\": {\n            \"mesh_term\": [\n                \"Botulinum Toxins, Type A\", \n                \"Botulinum Toxins\"\n            ]\n        }, \n        \"is_fda_regulated\": \"Yes\", \n        \"is_section_801\": \"Yes\", \n        \"lastchanged_date\": \"May 22, 2014\", \n        \"location\": {\n            \"facility\": {\n                \"address\": {\n                    \"city\": \"Seoul\", \n                    \"country\": \"Korea, Republic of\"\n                }\n            }, \n            \"status\": \"Not yet recruiting\"\n        }, \n        \"location_countries\": {\n            \"country\": \"Korea, Republic of\"\n        }, \n        \"number_of_arms\": \"1\", \n        \"overall_contact\": {\n            \"email\": \"clinicaltrials@allergan.com\", \n            \"last_name\": \"Allergan Inc.\"\n        }, \n        \"overall_official\": {\n            \"affiliation\": \"Allergan\", \n            \"last_name\": \"Medical Director\", \n            \"role\": \"Study Director\"\n        }, \n        \"overall_status\": \"Not yet recruiting\", \n        \"oversight_info\": {\n            \"authority\": \"South Korea: Korea Food and Drug Administration (KFDA)\", \n            \"has_dmc\": \"No\"\n        }, \n        \"phase\": \"Phase 4\", \n        \"primary_completion_date\": {\n            \"#text\": \"January 2015\", \n            \"@type\": \"Anticipated\"\n        }, \n        \"primary_outcome\": {\n            \"measure\": \"Percentage of Patients with Adverse Events\", \n            \"safety_issue\": \"No\", \n            \"time_frame\": \"28 Days\"\n        }, \n        \"required_header\": {\n            \"download_date\": \"ClinicalTrials.gov processed this data on June 09, 2014\", \n            \"link_text\": \"Link to the current ClinicalTrials.gov record.\", \n            \"url\": \"http://clinicaltrials.gov/show/NCT02147561\"\n        }, \n        \"responsible_party\": {\n            \"responsible_party_type\": \"Sponsor\"\n        }, \n        \"secondary_outcome\": [\n            {\n                \"measure\": \"Change from Baseline in Headache Impact Test-6 (HIT-6) Total Score\", \n                \"safety_issue\": \"No\", \n                \"time_frame\": \"Baseline, Day 28\"\n            }, \n            {\n                \"measure\": \"Physician Global Assessment of Outcome on a 3-Point Scale\", \n                \"safety_issue\": \"No\", \n                \"time_frame\": \"Day 28\"\n            }\n        ], \n        \"source\": \"Allergan\", \n        \"sponsors\": {\n            \"lead_sponsor\": {\n                \"agency\": \"Allergan\", \n                \"agency_class\": \"Industry\"\n            }\n        }, \n        \"start_date\": \"June 2014\", \n        \"study_design\": \"Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment\", \n        \"study_type\": \"Interventional\", \n        \"verification_date\": \"May 2014\"\n    }\n}", 
    "tags": [
        "clinicaltrials.gov", 
        "clinical trial"
    ], 
    "title": "A Safety and Efficacy Study of BOTOX\u00ae in Korean Adults With Chronic Migraine", 
    "url": "http://clinicaltrials.gov/show/NCT02147561", 
    "versions": []
}